Evidence map›Paper›PMID 38555858›Full record

ArticleJournal of biomolecular structure & dynamics2025

Computational identification of potential modulators of heme-regulated inhibitor (HRI) for pharmacological intervention against sickle cell disease.

Afolabi J Owoloye, Samuel O Olubode, Adewale Ogunleye, Emmanuel T Idowu, Kolapo M Oyebola

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of biomolecular structure & dynamics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 3 countries.

Afolabi J OwoloyeCentre for Genomic Research in Biomedicine (CeGRIB), Mountain Top University, Ibafo, Nigeria.
Samuel O OlubodeDepartment of Biochemistry, Adekunle Ajasin University, Akungba, Ondo State, Nigeria.
Adewale OgunleyeDepartment of Microbiology, Biocenter, University of Würzburg, Würzburg, Germany.
Emmanuel T IdowuParasitology and Bioinformatics Unit, Department of Zoology, Faculty of Science, University of Lagos, Lagos, Nigeria.
Kolapo M OyebolaCentre for Genomic Research in Biomedicine (CeGRIB), Mountain Top University, Ibafo, Nigeria.
Institute for Biomedicine · ITAdekunle Ajasin University · NGUniversity of Lagos · NGUniversity of Würzburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sickle cell disease (SCD) poses a significant health challenge and therapeutic approaches often target fetal hemoglobin (HbF) to ameliorate symptoms. Hydroxyurea, a current therapeutic option for SCD, has shown efficacy in increasing HbF levels. However, concerns about myelosuppression and thrombocytopenia necessitate the exploration of alternative compounds. Heme-regulated inhibitor (HRI) presents a promising target for pharmacological intervention in SCD due to its association with HbF modulation. This study screened compounds for their potential inhibitory functions against HRI. Small-molecule compounds from 17 folkloric plants were subjected to

Indexed as

Anemia, Sickle CellHemeFetal HemoglobinHumansMolecular Docking SimulationMolecular Dynamics SimulationProtein BindingFetal HemoglobinHemefetal hemoglobinheme-regulated inhibitorMMGBSAmolecular dockingSickle cell

Identifiers

PMID38555858
OpenAlexW4393352281

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.